Medtronic praises NICE guidance establishing hybrid closed loop therapy as standard of care for people with type 1 diabetes in the United Kingdom

New guidelines will expand access to automated insulin delivery technology among wider population.

Medtronic plc, the leading global healthcare technology company, applauds the guidance* published by the National Institute for Health and Care Excellence (NICE) in the United Kingdom recommending the use of hybrid closed loop systems for managing blood glucose levels in the management of type 1 diabetes in England & Wales. This multi technology appraisal, to be implemented in a phased approach over 5 years, will expand access to the most advanced automated insulin delivery (AID) systems which will help simplify diabetes management and improve glycemic outcomes for an additional 150,000 people regardless of their location or social background within these regions.

Priority will be given to children, pregnancy (including women trying for pregnancy), and adults with a HbA1c of 7.5% or above, or who have disabling hypoglycemia, despite optimal management with legacy technology.

"We've witnessed universal coverage of CGM in England & Wales shatter tech barriers for underserved communities, unleashing diabetes empowerment for all. With this decision, the benefits of hybrid closed loop therapy, the most advanced diabetes technology on the market, will be available as standard to the vast majority, regardless of background. This will make the UK one of the most progressive countries in terms of treating type 1 diabetes," said Professor Partha Kar, National Speciality Advisor, Diabetes, NHS England.

"This decision reinforces that CGM alone is not enough to manage diabetes and recognizes that hybrid closed loop systems can, and should, be considered as standard of care for people with type 1 diabetes," said Susan Monaghan, Senior Business Director for Medtronic Diabetes in the United Kingdom, Ireland and BeNeLux region. "While there are clinical and legitimate reasons for a person to decide not to use a hybrid closed loop system, the healthcare provider who does not offer such technology for a qualifying person living with type 1 diabetes should justify the reason why they are not doing so given the elimination of cost. This will ensure equitable access across the country."

The MiniMed™ 780G system features an advanced hybrid closed loop algorithm that automatically adjusts basal insulin delivery and autocorrection boluses every five minutes as needed based on real-time CGM glucose readings to keep blood sugar levels in a healthy Time in Range. Commercially available since 2020, real-world data on over 100,000 users has consistently demonstrated strong and sustained clinical outcomes with an average Time in Range of 72 percent and 78 percent for those using recommended settings. This real-world data strengthens the growing body of clinical evidence showing the MiniMed™ 780G system can help individuals with type 1 diabetes maintain good glucose control, resulting in a decrease in long-term complications resulting from prolonged hyperglycemia (high blood sugar levels) such as eye disease, kidney disease, and heart disease[1].

As the leading healthcare technology company with a comprehensive ecosystem combining advanced hybrid closed loop technology, CGM and value-added services to people with diabetes and physicians, Medtronic is well positioned to deliver on the promises to people living with diabetes in the UK and beyond and looks forward to partnering with National Healthcare Trusts in England and Wales as they implement the new guidelines.

* Consultees and commentators can appeal the committee's decision during the next two weeks. Final guidance is expected to publish in December 2023. https://www.nice.org.uk/news/article/nice-recommends-life-changing-technology-is-rolled-out-to-people-with-type-1-diabetes

[1] *Beck RW. The Association of Time in Range and Diabetic Complications: The Evidence Is Strong. Diabetes technology & therapeutics 2023;25(6):375-377. (In eng). DOI: 10.1089/dia.2023.0141.*

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our

technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
